Registry study for starting or switching atopic eczema medicines
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study follows people with atopic eczema when they start or switch to a specific medicine that affects the immune system. It helps doctors understand how these treatments work in real life, including for skin symptoms and daily quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have atopic eczema (eczema) that is severe or affects your daily life
- You are starting a specific immune-related eczema medicine for the first time, or switching to a specific one
- This new/switch medicine is not the same one you have taken before
- You understand the study (you and/or your parent/guardian for children) and agree to follow its rules
- You are not currently in a randomized clinical trial for eczema
- You plan to stay in the area for the next 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests different treatments for atopic dermatitis (eczema) by looking at changes in skin health. It may help people find safer, more effective ways to control moderate to severe eczema and related skin infections.
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
This registry collects information about people with atopic eczema who begin light therapy (phototherapy) or medicine that changes the immune system. It may help doctors better understand how these treatments work in everyday care in the Netherlands.
This study is a registry for people with eczema (atopic dermatitis) who are under 26 and have taken or plan to take body-wide treatments like pills or injections. By joining, you help researchers track how these treatments work over time.
This study tests an oral medication (EC-18) for moderate to severe atopic dermatitis (eczema) to see if it can improve symptoms like itching and skin rash. It may be an option for people whose eczema is not controlled by topical treatments.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
Hear when a new Dermatitis, Atopic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.